Ceftazidime-Avibactam Renal Dose Adjustment
For patients with renal impairment, ceftazidime-avibactam requires dose reduction based on creatinine clearance (CrCL), with the standard dose of 2.5 g IV every 8 hours adjusted to lower doses and/or extended intervals as renal function declines. 1
Standard Dosing by Renal Function
The FDA-approved dosing adjustments for ceftazidime-avibactam are based on estimated CrCL using the Cockcroft-Gault equation 1:
Dosing Table
- CrCL >50 mL/min: 2.5 g (2 g ceftazidime/0.5 g avibactam) IV every 8 hours
- CrCL 31-50 mL/min: 1.25 g IV every 8 hours
- CrCL 16-30 mL/min: 0.94 g IV every 12 hours
- CrCL 6-15 mL/min: 0.94 g IV every 24 hours
- CrCL ≤5 mL/min: 0.94 g IV every 48 hours
Hemodialysis Patients
For patients on hemodialysis, administer ceftazidime-avibactam after each dialysis session on dialysis days 1. Both ceftazidime and avibactam are removed by hemodialysis, necessitating post-dialysis dosing to maintain therapeutic levels.
Clinical Guidelines Support
Recent guidelines consistently recommend ceftazidime-avibactam 2.5 g IV every 8 hours for carbapenem-resistant Enterobacterales (CRE) infections in patients with normal renal function 2. These guidelines emphasize the importance of appropriate renal dose adjustment but do not provide detailed alternative regimens beyond the FDA recommendations.
Critical Considerations for Severe Infections
Extended Infusion Strategy
For critically ill patients or those with severe infections, consider extending the infusion time to 3 hours rather than the standard 2 hours, particularly when treating organisms with higher MICs 2, 3. This approach optimizes the time that drug concentrations remain above the MIC, which is the key pharmacodynamic driver for β-lactam efficacy.
Augmented Renal Clearance
In critically ill patients with augmented renal clearance (CrCL >130 mL/min), standard dosing may result in subtherapeutic levels. Recent research suggests these patients may require higher doses or continuous infusion to achieve adequate exposure 4, 5.
Risk of Underdosing in Renal Impairment
A critical caveat: Recent observational data indicate that renal-adjusted doses may be associated with higher mortality in bloodstream infections caused by KPC-producing organisms 6. This suggests that the recommended dose reductions, while preventing toxicity, may provide inadequate drug exposure for severe infections. In patients with renal impairment and life-threatening infections, therapeutic drug monitoring should be strongly considered to ensure adequate exposure while avoiding neurotoxicity.
Neurotoxicity Risk
Ceftazidime accumulation in renal impairment can lead to serious neurological complications including seizures, encephalopathy, and myoclonus 1. The risk increases when trough concentrations exceed 80-104 mg/L 7. Monitor patients with renal impairment closely for neurological symptoms, particularly confusion, altered mental status, or involuntary movements, and reduce the dose or extend the interval if these occur.
Practical Implementation
Initial Dosing
- Calculate CrCL using the Cockcroft-Gault equation with actual body weight
- Select the appropriate dose from the table above
- Administer as a 2-hour IV infusion (extend to 3 hours for severe infections or high MIC organisms)
Monitoring
- Reassess renal function every 48-72 hours in critically ill patients, as acute kidney injury or recovery can necessitate dose adjustment
- For patients on continuous renal replacement therapy (CRRT), standard dosing may result in excessive drug accumulation; consider dose reduction and therapeutic drug monitoring 7
- In hemodialysis patients, ensure dosing occurs after dialysis sessions to prevent premature drug removal
Special Populations
Patients with fluctuating renal function: When renal function is improving or worsening rapidly, err on the side of the more conservative (lower) dose initially, then adjust based on clinical response and repeat CrCL measurements within 24-48 hours.
CRRT patients: The standard every-8-hour regimen may cause excessive exposure. Consider 1.25-2.5 g every 12 hours depending on CRRT modality and effluent rate, with therapeutic drug monitoring if available 7.